55-97-0
55-97-0 結(jié)構(gòu)式
基本信息
六甲溴銨
溴化六甲雙銨
溴化六烴季銨
溴化六烴季銨C6
六次甲基雙-1,6-溴化三甲銨
六亞甲基-1,6-雙(三甲基溴化銨)
六亞甲基-1,6-雙溴化三甲銨
溴化己烷雙銨
溴化六亞甲基雙三甲銨
HEXAMETHONIUM DIBROMIDE
HEXAMETHYLENEBIS(TRIMETHYLAMMONIUM BROMIDE)
HEXANE-1,6-BIS(TRIMETHYLAMMONIUM BROMIDE)
N,N,N,N',N',N'-HEXAMETHYLHEXAMETHYLENEDIAMMONIUM DIBROMIDE
6-hexanediaminium,n,n,n,n’,n’,n’-hexamethyl-dibromide
alpha,omega-bis(trimethylammonium)hexanedibromide
esametina
gangliostat
hexamethioniumbromide
hexamethylenebis(trimethyl-ammoniudibromide
hexameton
hexoniumdibromide
simpatoblock
vegolysen
vegolysin
Hexane-1,6-bis(trimethylammonium bromide), N,N,N,Nμ,Nμ,Nμ-Hexamethylhexamethylenediammonium dibromide
Hexamethonium bromide ,98%
HEXAMETHONIUM BROMIDE HYDRATE, 98+%
Methobromine
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
知名試劑公司產(chǎn)品信息
Hexamethonium Bromide,>98.0%(T)(55-97-0)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/03/03 | S4069 | 溴化六甲銨 Hexamethonium?Dibromide | 55-97-0 | 50mg | 794.99元 |
| 2025/12/22 | HY-B0569 | 溴化六甲銨 Hexamethonium Bromide | 55-97-0 | 500mg | 100元 |
| 2025/12/22 | HY-B0569 | 溴化六甲銨 Hexamethonium Bromide | 55-97-0 | 10mM * 1mLin DMSO | 110元 |
常見問題列表
| Target | Value |
| Dopamine subtype 2 receptor | |
| AChR |
Hexamethonium Bromide能有效抵抗Ach和卡巴膽堿(CCh)對(duì)大鼠肩胛舌骨肌終板振幅的響應(yīng)，EC50分別為300 μM和100 μM。0.6 μM 筒箭毒堿存在下，Hexamethonium Bromide (50-200 μM)使神經(jīng)誘發(fā)的終板電流(e.p.cs)的振幅增加。在大鼠肌肉勻漿中，Hexamethonium Bromide也是乙酰膽堿酯酶活性的弱抑制劑，EC50為1.5 mM。在大鼠一側(cè)膈肌中，Hexamethonium Bromide (200 μM)降低終板電流(e.p.cs) (降低~25%)和微終板電流(m.e.p.cs) (降低~20%)衰變的時(shí)間常數(shù)。在低頻刺激(0.5-2 Hz)下，Hexamethonium Bromide (200 μM)增加30-40% e.p.c.量子含量。
Hexamethonium Bromide (0.2-25 mg/kg; i.v.) significantly reduces the renal sympathetic nerve activity (RSNA), mean arterial pressure (MAP) and heart rate (HR) in the Wistar rats and the spontaneously hypertensive rats (SHRs).
Hexamethonium Bromide (0.2-1.0 mg/kg; i.v.) treatments show no significant differences in the RSNA, MAP or HR between Wistar rats and SHRs.
Hexamethonium Bromide (5.0-25 mg/kg; i.v.) results in a greater reduction in the RSNA and MAP in SHRs compared with Wistar rats.
| Animal Model: | Male normotensive Wistar rats (280-320 g), SHRs |
| Dosage: | 0.2 mg/kg, 1.0 mg/kg, 5.0 mg/kg, 25 mg/kg |
| Administration: | Intravenous injection |
| Result: | Significantly reduced the RSNA, MAP and HR in the Wistar rats and the SHRs. |